#United States #Louisville, Kentucky #Ketamine #Cognision #EEG

A Groundbreaking Study on Ketamine's Effects

Cognision, a trailblazer in neurophysiological biomarker research, has recently published a pivotal study in the prestigious journal Biological Psychiatry. This research, titled Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers A Disordinal Effect, unveils a significant neurophysiological biomarker that indicates ketamine’s effects vary considerably between individuals. The phenomenon has been termed a "disordinal effect," marking an important advancement in understanding how different patients respond to this treatment.

The Growing Interest in Ketamine as a Treatment

Ketamine, alongside its derivative esketamine (marketed as SPRAVATO®), has gained traction in treating mental health disorders like depression, PTSD, and anxiety. The EEG/ERP Biomarker Qualification Consortium, which includes Cognision and ten pharmaceutical companies focused on CNS (central nervous system) disorders, embarked on this study to explore the precise changes ketamine induces in brain activity. Previous research by this consortium established distinctions between healthy individuals and those diagnosed with schizophrenia, but this new work pushes boundaries even further.

Discovery of Disordinal Effects

Cognision’s researchers posited that certain electrophysiological response patterns, known as ERP biomarkers, would react diversely to ketamine in different individuals. Specifically, they theorized that the direction of these effects could be predicted utilizing baseline measurements taken prior to administration. To validate this hypothesis, they implemented a controlled study involving 24 participants who periodically received sub-anesthetic doses of ketamine and a placebo across three separate visits in a randomized sequence. The primary focus was on the mismatch negativity amplitude (MMNa), which previous studies indicated would decrease consistently across subjects following ketamine treatment.

In a surprising twist, results indicated that individuals with a substantial baseline MMNa showed the anticipated reduction post-treatment, while those with lower baseline MMNa exhibited an unexpected increase, confirming the hypothesis of a disordinal effect. The concurrency of these findings across multiple studies adds robustness to the claim, showcasing a statistically significant level of evidence.

Implications for Future Treatment and Drug Development

Dr. Igor Korolev, the Director of Biomarkers and Digital Health at Cognision, highlighted the significance of these findings, noting that pharmaceutical companies have observed similar patterns in their studies but previously dismissed them as anomalies. This revelation emphasizes a possible need to revisit existing data in light of the newly uncovered disordinal effects.

Such developments carry substantial implications for personalized medicine, notably for drug design and clinical trials aimed at CNS disorders. The capability to predict both the intensity and the nature of a patient’s response based on quantifiable biomarkers could transform how practitioners choose therapeutic approaches for individuals. Dr. Marco Cecchi, Chief Science Officer at Cognision, echoed this sentiment, asserting that their results may help elucidate why certain patients with depression do not respond positively to ketamine therapy, thereby paving the way for more targeted interventions.

About Cognision and Its Commitment

Cognision is dedicated to advancing neurophysiological biomarker services tailored for clinical trials, offering a range of capabilities including EEG, ERP, PSG, eye-tracking, and cognitive evaluations. By ensuring comprehensive solutions—from protocol development to data analysis—Cognision emphasizes precision and regulatory compliance in pharmaceutical studies.

The EEG/ERP Biomarker Qualification Consortium continues to promote the integration of electrophysiological biomarkers in drug development, aiming to enhance the understanding and treatment of CNS disorders. For further insights and updates on their work, visit Cognision's website.

• ---

This groundbreaking study marks a pivotal moment in the landscape of mental health treatment, elucidating the importance of personalized approaches based on individual biomarker responses. As organizations like Cognision continue to innovate, the future of psychiatric care looks promising for those who have long struggled with mental health conditions.

Conclusion

With such significant findings, Cognision is not only leading the charge in neurobiological research but also setting a precedent for future studies that can help tailor treatment modalities to meet the unique needs of each patient suffering from psychiatric illnesses.